- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Methotrexate
別名: NCI-C04671, Amethopterin, CL14377, WR19039 中文名稱：甲氨蝶呤
此產(chǎn)品請避光密封保存。
Methotrexate,一種葉酸類似物，是細菌、癌細胞和正常細胞中dihydrofolate reductase(DHFR)的非選擇性抑制劑，與DHFR、NADPH形成無活性的三元復合物。Methotrexate (MTX)可誘導凋亡。
Methotrexate Chemical Structure
CAS: 59-05-2
產(chǎn)品質(zhì)控
批次：
純度：
99.79%
99.79
Methotrexate相關(guān)產(chǎn)品
| 相關(guān)產(chǎn)品 | Camptothecin (CPT) SN-38 Triptolide (+)-Bicuculline Rutin Pinocembrin BHQ Harmine hydrochloride Psoralen Lappaconite HBr Luteoloside Lycorine hydrochloride Tetrahydropalmatine hydrochloride | 點擊展開 |
|---|---|---|
| 相關(guān)化合物庫 | 代謝化合物庫 抗癌代謝化合物庫 谷氨酰胺代謝化合物庫 糖代謝化合物庫 脂代謝化合物庫 | 點擊展開 |
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| PC3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay, IC50 = 0.001 μM. | 20580561 | |
| OVCAR4 | Growth inhibition assay | 48 hrs | Growth inhibition of human OVCAR4 cells after 48 hrs by SRB staining method, GI50 = 0.002512 μM. | 17532099 | |
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.005 μM. | 20580561 | |
| KB | Antiproliferative assay | 96 hrs | Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs, IC50 = 0.006 μM. | 21879757 | |
| KB | Antiproliferative assay | 96 hrs | Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay, IC50 = 0.006 μM. | 29425443 | |
| KB | Growth inhibition assay | 96 hrs | Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay, IC50 = 0.006 μM. | 24111942 | |
| HL60 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HL60 cells after 48 hrs by trypan blue exclusion test, IC50 = 0.00692 μM. | 17497807 | |
| CCRF-CEM R30dm | Growth inhibition assay | 120 hrs | Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs, EC50 = 0.0079 μM. | 15615538 | |
| Tsu-Pr1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against Tsu-Pr1 cells after 72 hrs in folate depleted media, IC50 = 0.008 μM. | 17127067 | |
| KB | Function assay | 14 days | Inhibition of colony formation of human KB cells endogenously expressing RFC/FRalpha/PCFT incubated for 14 days by methylene blue staining based clonogenicty assay, IC50 = 0.0085 μM. | 22243528 | |
| PPC1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against PPC1 cells after 72 hrs in folate depleted media, IC50 = 0.01 μM. | 17127067 | |
| KB | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KB cells after 72 hrs by MTT assay in presence of leucovorin, IC50 = 0.01 μM. | 27017552 | |
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.01 μM. | 25668494 | |
| KB | Function assay | 72 hrs | Inhibition of TS/AICARFTase/GARFTase in human KB cells assessed as reduction in cell proliferation in folate free medium after 72 hrs in presence of leucovorin by MTT assay, IC50 = 0.01 μM. | 28830032 | |
| HL60 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50 = 0.012 μM. | 11170674 | |
| PC43-10 | Antiproliferative assay | 96 hrs | Antiproliferative activity against chinese hamster PC43-10 expressing human RFC assessed as reduction of viable cells after 96 hrs, IC50 = 0.012 μM. | 21879757 | |
| PC43-10 | Antiproliferative assay | 96 hrs | Binding affinity to human RFC expressed in Chinese hamster PC43-10 cells assessed as antiproliferative activity measured as reduction in cell viability after 96 hrs by Cell-Titer Blue assay, IC50 = 0.012 μM. | 29425443 | |
| PC43-10 | Growth inhibition assay | 96 hrs | Growth inhibition of Chinese hamster PC43-10 cells after 96 hrs by CellTiter-blue assay, IC50 = 0.012 μM. | 24111942 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.013 μM. | 25668494 | |
| SW620 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay in presence of leucovorin, IC50 = 0.013 μM. | 27017552 | |
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTS assay, IC50 = 0.0135 μM. | 28152430 | |
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTS assay, GI50 = 0.014 μM. | 28711701 | |
| CCRF-CEM R30dm | Growth inhibition assay | 120 hrs | Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs, EC50 = 0.0145 μM. | 16279780 | |
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, GI50 = 0.015 μM. | 28177228 | |
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay, GI50 = 0.015 μM. | 26994844 | |
| 5637 | Cytotoxicity assay | 96 hrs | Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining, IC50 = 0.016 μM. | 19243173 | |
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against A549 cells after 72 hrs in folate depleted media, IC50 = 0.02 μM. | 17127067 | |
| KB | Antiproliferative assay | 96 hrs | Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid, IC50 = 0.02 μM. | 21879757 | |
| KB | Antiproliferative assay | 96 hrs | Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs in presence of folic acid by Cell-Titer Blue assay, IC50 = 0.02 μM. | 29425443 | |
| KB | Growth inhibition assay | 96 hrs | Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid, IC50 = 0.02 μM. | 24111942 | |
| KB | Cytotoxicity assay | up to 96 hrs | Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay, IC50 = 0.02 μM. | 25234128 | |
| IGROV1 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs, IC50 = 0.021 μM. | 21879757 | |
| IGROV1 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid, IC50 = 0.022 μM. | 21879757 | |
| SW620 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SW620 cells in folate free medium after 72 hrs in presence of leucovorin by MTT assay, IC50 = 0.022 μM. | 28830032 | |
| HL60 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay, IC50 = 0.0227 μM. | 28152430 | |
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, GI50 = 0.024 μM. | 28177228 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, GI50 = 0.024 μM. | 26994844 | |
| GUMBUS | Cytotoxicity assay | 72 hrs | Cytotoxicity against human GUMBUS cells after 72 hrs by MTT assay, IC50 = 0.024 μM. | 23031590 | |
| CCRF-CEM | Function assay | Inhibitory concentration against dihydrofolate reductase (DHFR) enzyme isolated from CCRF-CEM human leukemia cells, IC50 = 0.00082 μM. | 8691451 | ||
| CCRF-CEM | Function assay | Inhibitory activity against Dihydrofolate reductase (DHFR) isolated from CCRF-CEM human leukemia cells in experiment 1, IC50 = 0.00072 μM. | 8568827 | ||
| CCRF-CEM | Function assay | Inhibitory activity against Dihydrofolate reductase (DHFR) isolated from CCRF-CEM human leukemia cells in experiment 2, IC50 = 0.0006 μM. | 8568827 | ||
| L1210 | Function assay | Inhibition of the dihydrofolate reductase enzyme(DHFR) derived from L1210 murine leukemia cells, Ki = 0.000006 μM. | 1732549 | ||
| L1210 | Function assay | In vitro inhibitory activity against L1210 dihydrofolate reductase in rodent neoplastic cells, Ki = 0.000006 μM. | 7108907 | ||
| L1210 | Function assay | Inhibition of Dihydrofolate reductase (DHFR) enzyme derived from L1210 cells expressed as Ki (pM), Ki = 0.0000058 μM. | 8340923 | ||
| L1210 | Function assay | Concentration inhibiting dihydrofolate reductase derived from L1210 cells, Ki = 0.0000056 μM. | 2296020 | ||
| L1210 | Function assay | Evaluated for inhibition of dihydrofolate reductase (DHFR) isolated from L1210 cells, Ki = 0.0000055 μM. | 3184124 | ||
| L1210 | Function assay | Compound was evaluated for inhibitory effect on dihydrofolate reductase (DHFR) from L1210 cells at Inhibitory constant (n=3), Ki = 0.0000055 μM. | 2423690 | ||
| L1210 | Function assay | The compound was tested for its inhibitory activity against Dihydrofolate reductase derived from L1210 cells, Ki = 0.0000053 μM. | 1732551 | ||
| L1210 | Function assay | Inhibitory activity of Dihydrofolate reductase in L1210 cells, Ki = 0.0000048 μM. | 8277497 | ||
| L1210 | Function assay | In vitro inhibition of dihydrofolate reductase (DHFR) in L1210 cells, Ki = 0.0000048 μM. | 1501226 | ||
| L1210 | Function assay | Compound was evaluated for binding affinity against Dihydrofolate reductase of L1210 cells, Ki = 0.0000044 μM. | 3712374 | ||
| L1210 | Function assay | Inhibition of Dihydrofolate reductase in mouse L1210 cells, Ki = 0.0000043 μM. | 7057425 | ||
| L1210 | Function assay | Compound was evaluated for inhibitory activity against DHFR in L1210 cells, Ki = 0.0000032 μM. | 3091834 | ||
| L1210 | Function assay | Concentration required for 50% inhibition against L1210 cells, IC50 = 0.00084 μM. | 6403710 | ||
| CCRF-CEM | Function assay | Inhibitory activity against Dihydrofolate reductase (DHFR) isolated from CCRF-CEM human leukemia cells in experiment 1, IC50 = 0.00118 μM. | 8568827 | ||
| CCRF-CEM | Function assay | Inhibitory activity against Dihydrofolate reductase (DHFR) isolated from CCRF-CEM human leukemia cells in experiment 2, IC50 = 0.0014 μM. | 8568827 | ||
| L1210 | Growth inhibition assay | Cell growth inhibition against mouse leukemia L1210 cells, IC50 = 0.002 μM. | 3872941 | ||
| L1210 | Growth inhibition assay | Compound was tested for its ability to inhibit growth of L1210 mouse leukemia cells, IC50 = 0.002 μM. | 2871191 | ||
| L1210 | Growth inhibition assay | Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells, IC50 = 0.002 μM. | 3462394 | ||
| L1210 | Growth inhibition assay | Evaluated for cell growth inhibition of L1210 cells in cultures, IC50 = 0.0021 μM. | 3184124 | ||
| H.Ep.-2 | Function assay | Tested for cloning suppression test against H.Ep.-2 cells, ED50 = 0.0024 μM. | 7365749 | ||
| H.Ep.-2 | Function assay | Effective dose against H.Ep.-2 cells, ED50 = 0.0024 μM. | 7057425 | ||
| L1210 | Growth inhibition assay | Compound was evaluated for growth inhibition and minimal inhibitory concentration was reported against L1210 cells, MIC50 = 0.00248 μM. | 3712374 | ||
| L1210 | Growth inhibition assay | Compound was evaluated for growth inhibition in L1210 murine leukemia cells, IC50 = 0.0025 μM. | 3091834 | ||
| L1210 | Growth inhibition assay | Compound was evaluated for inhibitory effect on growth of L1210 cells at IC50 (n=4), IC50 = 0.00255 μM. | 2423690 | ||
| L1210 | Growth inhibition assay | Inhibitory concentration of compound in growth of L-1210 cells, IC50 = 0.0027 μM. | 6793726 | ||
| L1210 | Growth inhibition assay | In vitro inhibition of L1210 cell growth in rodent neoplastic cells, IC50 = 0.0027 μM. | 7108907 | ||
| L1210 | Function assay | Concentration of inhibitor to decrease binding of [3H]MTX radioligand to Dihydrofolate reductase from L1210 cells by 50%, ID50 = 0.0027 μM. | 6811744 | ||
| L1210 | Growth inhibition assay | Minimum inhibitory concentration of compound was tested for growth inhibition of L1210 cells, MIC50 = 0.00271 μM. | 7143361 | ||
| CEM | Growth inhibition assay | Compound is tested for the inhibition of growth of human lymphoblastic leukemia cells (CEM), ID50 = 0.003 μM. | 6787199 | ||
| RBL | Growth inhibition assay | Compound is tested for the inhibition of growth of rat basophilic leukemia (RBL)cells, ID50 = 0.003 μM. | 6787199 | ||
| WIL2 | Function assay | Inhibitory activity against dihydrofolate reductase (DHFR) obtained from human WIL2 cells, IC50 = 0.0038 μM. | 3339615 | ||
| L1210 | Growth inhibition assay | Tested for growth inhibition of L1210 leukemia cells, IC50 = 0.0039 μM. | 3121855 | ||
| L1210 | Growth inhibition assay | Concentration required to inhibit 50% growth of L1210 cells in culture, IC50 = 0.0039 μM. | 1732549 | ||
| L1210 | Growth inhibition assay | Inhibition of the growth of methotrexate sensitive L1210 leukemia/S cells in culture, IC50 = 0.0044 μM. | 2704031 | ||
| L1210 | Growth inhibition assay | Inhibition of cell growth of murine L-1210 cells, IC50 = 0.0045 μM. | 3373490 | ||
| L1210 | Function assay | Inhibitory concentration was evaluated as the concentration required for inhibition of L1210 cells, IC50 = 0.00451 μM. | 1732551 | ||
| L1210 | Growth inhibition assay | Tested for cell-growth inhibition against mouse leukemic L1210 cells, IC50 = 0.0046 μM. | 2898531 | ||
| L1210 | Growth inhibition assay | Compound was evaluated for the growth inhibition of L1210 cells, IC50 = 0.0046 μM. | 1995880 | ||
| P388D1 | Cytotoxicity assay | Cytotoxic activity was evaluated against P388D1 tumor cells, IC50 = 0.0048 μM. | 8632413 | ||
| L1210 | Function assay | Inhibitory activity against cultured L1210 cells, IC50 = 0.005 μM. | 3351853 | ||
| S180 | Function assay | Concentration required for 50% inhibition against S180 cells, IC50 = 0.0054 μM. | 6403710 | ||
| KB | Antiproliferative assay | Antiproliferative activity against human RFC and FRalpha expressing human KB cells, IC50 = 0.006 μM. | 18680275 | ||
| KB | Growth inhibition assay | Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay, IC50 = 0.006 μM. | 25234128 | ||
| P388 | Function assay | Compound was tested for the inhibition of dihydrofolate reductase in P388 cells, IC50 = 0.0066 μM. | 8201595 | ||
| L1210 | Function assay | Compound is evaluated for binding to L1210 mouse leukemia cells dihydrofolate reductase using kinetic assay, ID50 = 0.0068 μM. | 6787199 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition of human CCRF-CEM cells, EC50 = 0.0082 μM. | 15615538 | ||
| L tumor cells | Cytotoxicity assay | Cytotoxic activity was evaluated against L tumor cells, IC50 = 0.0083 μM. | 8632413 | ||
| 143B (TK-) | Cytotoxicity assay | Cytotoxic Activity was evaluated against 143B (TK-) tumor cells, IC50 = 0.0088 μM. | 8632413 | ||
| HaTu80 | Growth inhibition assay | In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells HaTu80, IC50 = 0.009 μM. | 6694171 | ||
| HaTu80 | Function assay | Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by HuTu 80 assay, IC50 = 0.009 μM. | 3968685 | ||
| L1210 | Growth inhibition assay | Inhibition of cell growth against L1210 murine leukemia cells, IC50 = 0.009 μM. | 2918496 | ||
| L1210 | Growth inhibition assay | Compound was evaluated for cell growth inhibition of murine (L1210) leukemic cells, IC50 = 0.009 μM. | 1992122 | ||
| Daoy | Cytotoxicity assay | Cytotoxic activity was evaluated against Daoy tumor cells, IC50 = 0.009 μM. | 8632413 | ||
| Vero | Cytotoxicity assay | Cytotoxic Activity was evaluated against Vero tumor cells, IC50 = 0.0092 μM. | 8632413 | ||
| L1210 | Growth inhibition assay | Inhibition of growth in L1210 murine leukemia cells in culture expressed as IC50 (nM), IC50 = 0.0095 μM. | 8340923 | ||
| H460 | Cytotoxicity assay | Cytotoxic Activity was evaluated against H460 tumor cells, IC50 = 0.0095 μM. | 8632413 | ||
| L1210 | Growth inhibition assay | Compound is tested for the inhibition of growth of murine leukemia cells (L1210), ID50 = 0.01 μM. | 6787199 | ||
| L1210 | Growth inhibition assay | Inhibitory concentration against the growth of L1210 murine leukemia cells in tissue culture, IC50 = 0.01 μM. | 4009615 | ||
| H35FF | Growth inhibition assay | Inhibition of growth of H35FF cells, IC50 = 0.01 μM. | 2542557 | ||
| H35N | Growth inhibition assay | Inhibition of growth of H35N cells, IC50 = 0.01 μM. | 2542557 | ||
| S180 | Growth inhibition assay | Tested for the ability to inhibit growth in vitro against S180 cells, IC50 = 0.01 μM. | 8277497 | ||
| FaDu | Growth inhibition assay | Growth inhibition of human squamous cell carcinoma FaDu cells during continuous Exposure (0-12 h), EC50 = 0.0113 μM. | 10956221 | ||
| L1210/S | Growth inhibition assay | Evaluated for the growth inhibition of L1210 /S cells, IC50 = 0.012 μM. | 3968685 | ||
| U373MG | Cytotoxicity assay | Cytotoxic activity was evaluated against U373MG tumor cells, IC50 = 0.012 μM. | 8632413 | ||
| PC43-10 | Antiproliferative assay | Antiproliferative activity against human RFC expressing Chinese hamster PC43-10 cells, IC50 = 0.012 μM. | 18680275 | ||
| PC43-10 | Growth inhibition assay | Inhibition of RFC (unknown origin) expressed in Chinese hamster PC43-10 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay, IC50 = 0.012 μM. | 25234128 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition of human CCRF-CEM cells, EC50 = 0.0125 μM. | 16279780 | ||
| CCRF-CEM | Cytotoxicity assay | Cytotoxicity against human CCRF-CEM cells, EC50 = 0.0125 μM. | 18605720 | ||
| Ehrlich cells | Function assay | Concentration required for 50% inhibition against Ehrlich cells, IC50 = 0.0126 μM. | 6403710 | ||
| WI-L2 | Growth inhibition assay | Inhibition of cell growth against WI-L2 cells, IC50 = 0.013 μM. | 2918496 | ||
| WI-L2 | Growth inhibition assay | Compound was evaluated for cell growth inhibition of human (WI-L2) leukemic cells, IC50 = 0.013 μM. | 1992122 | ||
| A253 | Growth inhibition assay | The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells, EC50 = 0.013 μM. | 7562910 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibitory activity against CCRF-CEM human lymphoblastic leukemia cells, EC50 = 0.013 μM. | 16078850 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition of human CCRF-CEM cells, EC50 = 0.0133 μM. | 17552508 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition of parental CCRF-CEM cells, EC50 = 0.014 μM. | 11384244 | ||
| CCRF-CEM | Growth inhibition assay | Inhibition of growth in CCRF-CEM cells, EC50 = 0.014 μM. | 16451071 | ||
| chang liver cells | Growth inhibition assay | Concentration required to inhibit the growth of chang liver cells, IC50 = 0.014 μM. | 9022804 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition was measured as for inhibition of growth in CCRF-CEM cells, EC50 = 0.0143 μM. | 9554874 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition of CCRF-CEM human leukemia cells, EC50 = 0.0144 μM. | 10956221 | ||
| CCRF-CEM | Growth inhibition assay | Inhibitory activity against growth of CCRF-CEM human leukemia cells, ED50 = 0.0145 μM. | 8691451 | ||
| A253 | Growth inhibition assay | Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h), EC50 = 0.0145 μM. | 10956221 | ||
| CCRF-CEM | Growth inhibition assay | Inhibition of growth of CCRF-CEM human leukemia cells (n=4), EC50 = 0.0145 μM. | 11960504 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibitory activity against MTX resistant CCRF-CEM human lymphoblastic leukemia cells with decreased polyglutamylation, EC50 = 0.0145 μM. | 16078850 | ||
| SW480 | Growth inhibition assay | In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells SW480, IC50 = 0.015 μM. | 6694171 | ||
| SW480 | Function assay | Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by SW480 assay, IC50 = 0.015 μM. | 3968685 | ||
| SCC25 | Antitumor assay | Compound was tested for in vitro antitumor activity, using SCC25 human head and neck squamous carcinoma cells, IC50 = 0.015 μM. | 9857098 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition of CCRF-CEM cells resistant to MTX, EC50 = 0.015 μM. | 11384244 | ||
| CCRF-CEM R30dm | Growth inhibition assay | Growth inhibition of of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of FPGS, EC50 = 0.0157 μM. | 17552508 | ||
| D54 | Cytotoxicity assay | Cytotoxic Activity was evaluated against D54 tumor cells, IC50 = 0.016 μM. | 8632413 | ||
| CCRF-CEM R30dm | Growth inhibition assay | Growth inhibition of MTX-resistant human CCRF-CEM R30dm cells, EC50 = 0.0165 μM. | 15615522 | ||
| FaDu | Growth inhibition assay | The compound was tested for Growth inhibition of the human squamous cell carcinoma FaDu cells, EC50 = 0.017 μM. | 7562910 | ||
| CCRF-CEM | Growth inhibition assay | Inhibition of growth in MTX-resistant CCRF-CEM cell line, R30dm cells, EC50 = 0.017 μM. | 16451071 | ||
| CCRF-CEM | Growth inhibition assay | Growth inhibition of human CCRF-CEM cells, EC50 = 0.0175 μM. | 15615522 | ||
| HT-29 | Growth inhibition assay | In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells HT-29, IC50 = 0.018 μM. | 6694171 | ||
| HT-29 | Function assay | Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by HT-29 assay, IC50 = 0.018 μM. | 3968685 | ||
| L1210 | Cytotoxicity assay | cytotoxicity against L1210 cells, ID50 = 0.02 μM. | 6139480 | ||
| L1210 | Function assay | Compound was tested for its inhibitory concentration to inhibit the enzyme Dihydro Folate Reductase (DHFR) from murine L1210 leukemia cells, IC50 = 0.02 μM. | 3462394 | ||
| WI-L2 | Function assay | Compound was tested for its inhibitory activity against dihydrofolate reductase (DHFR), isolated from MTX-resistant WI-L2 cells, IC50 = 0.02 μM. | 2918496 | ||
| Vero | Function assay | Compound concentration required to reduce by 50% the number of fibroblast-like cells (Vero) after three cell cycles, ID50 = 0.02 μM. | 1548681 | ||
| Raji | Function assay | Compound concentration required to reduce by 50% the number of human B (Raji)cells after three cell cycles, ID50 = 0.02 μM. | 1548681 | ||
| L1210 | Growth inhibition assay | Concentration required to inhibit the growth of L1210 cells, IC50 = 0.02 μM. | 9022804 | ||
| KB | Antiproliferative assay | Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid, IC50 = 0.02 μM. | 18680275 | ||
| IGROV1 | Antiproliferative assay | Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells, IC50 = 0.021 μM. | 18680275 | ||
| U87MG | Cytotoxicity assay | Cytotoxic activity was evaluated against U87MG tumor cells, IC50 = 0.022 μM. | 8632413 | ||
| IGROV1 | Antiproliferative assay | Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid, IC50 = 0.022 μM. | 18680275 | ||
| A375 | Antiproliferative assay | Antiproliferative activity against human A375 cells, IC50 = 0.022 μM. | 27217001 | ||
| A549 | Antiproliferative assay | Antiproliferative activity against human A549 cells, IC50 = 0.022 μM. | 27217001 | ||
| HeLa | Antiproliferative assay | Antiproliferative activity against human HeLa cells, IC50 = 0.022 μM. | 27217001 | ||
| HepG2 | Antiproliferative assay | Antiproliferative activity against human HepG2 cells, IC50 = 0.022 μM. | 27217001 | ||
| HEK293 | Cytotoxicity assay | Cytotoxicity activity against HEK293 cells, IC50 = 0.022 μM. | 27217001 | ||
| A498 | Antiproliferative assay | Antiproliferative activity against human A498 cells, IC50 = 0.022 μM. | 27217001 | ||
| A549 | Antitumor assay | In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum, IC50 = 0.023 μM. | 9022795 | ||
| WI-L2/M4 | Function assay | Inhibition of dihydrofolate reductase (DHFR) from human cells (WI-L2/M4), IC50 = 0.024 μM. | 1995880 | ||
| WI-L2 | Growth inhibition assay | Compound was evaluated for the growth inhibition of WI-L2 cells, IC50 = 0.024 μM. | 1995880 | ||
| hPBMC | Growth inhibition assay | In vitro growth inhibition of human peripheral blood mononuclear cells (hPBMC), IC50 = 0.024 μM. | 9016334 | ||
| WIDR | Growth inhibition assay | In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells WIDR, IC50 = 0.025 μM. | 6694171 | ||
| CEM | Growth inhibition assay | In vitro cytotoxicity by its growth inhibitory activity against human leukemic lymphoblasts (CEM cells), IC50 = 0.025 μM. | 6585550 | ||
| WIDR | Function assay | Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by WIDR assay, IC50 = 0.025 μM. | 3968685 | ||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 0.0006915 μM. | SANGER | ||
| NCI-H1770 | Growth inhibition assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 0.001983 μM. | SANGER | ||
| DEL | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 0.003119 μM. | SANGER | ||
| ATN-1 | Growth inhibition assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 0.003924 μM. | SANGER | ||
| SK-NEP-1 | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 0.004819 μM. | SANGER | ||
| ML-2 | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.004967 μM. | SANGER | ||
| ALL-PO | Growth inhibition assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 0.005858 μM. | SANGER | ||
| BV-173 | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 0.006349 μM. | SANGER | ||
| RS4-11 | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.00705 μM. | SANGER | ||
| NCI-SNU-1 | Growth inhibition assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 0.007515 μM. | SANGER | ||
| NKM-1 | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 0.007702 μM. | SANGER | ||
| A3-KAW | Growth inhibition assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 0.008923 μM. | SANGER | ||
| HDLM-2 | Growth inhibition assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 0.01004 μM. | SANGER | ||
| HEL | Growth inhibition assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 0.01145 μM. | SANGER | ||
| MOLT-16 | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 0.0116 μM. | SANGER | ||
| LAMA-84 | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 0.01239 μM. | SANGER | ||
| 697 | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 0.01257 μM. | SANGER | ||
| MHH-PREB-1 | Growth inhibition assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 0.01323 μM. | SANGER | ||
| L-363 | Growth inhibition assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 0.01426 μM. | SANGER | ||
| KE-37 | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 0.01553 μM. | SANGER | ||
| JVM-3 | Growth inhibition assay | Inhibition of human JVM-3 cell growth in a cell viability assay, IC50 = 0.01604 μM. | SANGER | ||
| CTB-1 | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 0.01623 μM. | SANGER | ||
| NOMO-1 | Growth inhibition assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 0.01625 μM. | SANGER | ||
| ES1 | Growth inhibition assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 0.01639 μM. | SANGER | ||
| MV-4-11 | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.01935 μM. | SANGER | ||
| J-RT3-T3-5 | Growth inhibition assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 0.01942 μM. | SANGER | ||
| RPMI-8866 | Growth inhibition assay | Inhibition of human RPMI-8866 cell growth in a cell viability assay, IC50 = 0.01999 μM. | SANGER | ||
| MOLT-4 | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 0.02117 μM. | SANGER | ||
| DB | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 0.02128 μM. | SANGER | ||
| DOHH-2 | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 0.02156 μM. | SANGER | ||
| HAL-01 | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 0.02227 μM. | SANGER | ||
| HL-60 | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 0.02478 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 0.02686 μM. | SANGER | ||
| NBsusSR | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50 = 0.02958 μM. | SANGER | ||
| CGTH-W-1 | Growth inhibition assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 0.03121 μM. | SANGER | ||
| HH | Growth inhibition assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 0.0316 μM. | SANGER | ||
| GR-ST | Growth inhibition assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 0.03628 μM. | SANGER | ||
| COLO-684 | Growth inhibition assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 0.03755 μM. | SANGER | ||
| A4-Fuk | Growth inhibition assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 0.03823 μM. | SANGER | ||
| BE-13 | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 0.03875 μM. | SANGER | ||
| P12-ICHIKAWA | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 0.0413 μM. | SANGER | ||
| BCPAP | Growth inhibition assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 0.0431 μM. | SANGER | ||
| P30-OHK | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 0.04355 μM. | SANGER | ||
| 769-P | Growth inhibition assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 0.04526 μM. | SANGER | ||
| MS-1 | Growth inhibition assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 0.04526 μM. | SANGER | ||
| KYSE-270 | Growth inhibition assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 0.05211 μM. | SANGER | ||
| COLO-320-HSR | Growth inhibition assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 0.05238 μM. | SANGER | ||
| A2780 | Growth inhibition assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 0.05454 μM. | SANGER | ||
| EM-2 | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 0.05713 μM. | SANGER | ||
| K5 | Growth inhibition assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 0.0598 μM. | SANGER | ||
| MC116 | Growth inhibition assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 0.06061 μM. | SANGER | ||
| AU565 | Growth inhibition assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50 = 0.06134 μM. | SANGER | ||
| ONS-76 | Growth inhibition assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 0.06377 μM. | SANGER | ||
| MN-60 | Growth inhibition assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 0.06573 μM. | SANGER | ||
| SBC-5 | Growth inhibition assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 0.06936 μM. | SANGER | ||
| HT-3 | Growth inhibition assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 0.06937 μM. | SANGER | ||
| HC-1 | Growth inhibition assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 0.06957 μM. | SANGER | ||
| EW-13 | Growth inhibition assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 0.0723 μM. | SANGER | ||
| NB14 | Growth inhibition assay | Inhibition of human NB14 cell growth in a cell viability assay, IC50 = 0.07501 μM. | SANGER | ||
| CTV-1 | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 0.0771 μM. | SANGER | ||
| ES4 | Growth inhibition assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 0.07951 μM. | SANGER | ||
| ACHN | Growth inhibition assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 0.08526 μM. | SANGER | ||
| LU-134-A | Growth inhibition assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 0.08865 μM. | SANGER | ||
| HuO-3N1 | Growth inhibition assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 0.08909 μM. | SANGER | ||
| KYSE-510 | Growth inhibition assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 0.09172 μM. | SANGER | ||
| BB30-HNC | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 0.09428 μM. | SANGER | ||
| MLMA | Growth inhibition assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 0.09654 μM. | SANGER | ||
| KMOE-2 | Growth inhibition assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 0.09742 μM. | SANGER | ||
| MEG-01 | Growth inhibition assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 0.09944 μM. | SANGER | ||
| RPMI-8226 | Growth inhibition assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 0.1012 μM. | SANGER | ||
| MHH-ES-1 | Growth inhibition assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 0.10701 μM. | SANGER | ||
| NCI-H1792 | Growth inhibition assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 0.11424 μM. | SANGER | ||
| KYSE-150 | Growth inhibition assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 0.11506 μM. | SANGER | ||
| SW780 | Growth inhibition assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50 = 0.11629 μM. | SANGER | ||
| LS-411N | Growth inhibition assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 0.11759 μM. | SANGER | ||
| COR-L23 | Growth inhibition assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 0.12192 μM. | SANGER | ||
| COLO-800 | Growth inhibition assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 0.12372 μM. | SANGER | ||
| KARPAS-45 | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 0.12389 μM. | SANGER | ||
| IST-MEL1 | Growth inhibition assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 0.12638 μM. | SANGER | ||
| HT | Growth inhibition assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 0.13369 μM. | SANGER | ||
| QIMR-WIL | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 0.13941 μM. | SANGER | ||
| RT-112 | Growth inhibition assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 0.14231 μM. | SANGER | ||
| SNU-C2B | Growth inhibition assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50 = 0.14474 μM. | SANGER | ||
| GI-ME-N | Growth inhibition assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 0.14716 μM. | SANGER | ||
| ES7 | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 0.14836 μM. | SANGER | ||
| KGN | Growth inhibition assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 0.15012 μM. | SANGER | ||
| NCI-H2122 | Growth inhibition assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 0.15143 μM. | SANGER | ||
| HT-29 | Growth inhibition assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 0.15337 μM. | SANGER | ||
| D-392MG | Growth inhibition assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 0.15809 μM. | SANGER | ||
| COLO-741 | Growth inhibition assay | Inhibition of human COLO-741 cell growth in a cell viability assay, IC50 = 0.16212 μM. | SANGER | ||
| KM12 | Growth inhibition assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.16444 μM. | SANGER | ||
| EW-1 | Growth inhibition assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 0.16835 μM. | SANGER | ||
| DBTRG-05MG | Growth inhibition assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 0.17118 μM. | SANGER | ||
| LCLC-103H | Growth inhibition assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 0.17389 μM. | SANGER | ||
| U-2-OS | Growth inhibition assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 0.18232 μM. | SANGER | ||
| JAR | Growth inhibition assay | Inhibition of human JAR cell growth in a cell viability assay, IC50 = 0.18836 μM. | SANGER | ||
| 8305C | Growth inhibition assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 0.19634 μM. | SANGER | ||
| MG-63 | Growth inhibition assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 0.1971 μM. | SANGER | ||
| TYK-nu | Growth inhibition assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50 = 0.19727 μM. | SANGER | ||
| LOXIMVI | Growth inhibition assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 0.20186 μM. | SANGER | ||
| CHL-1 | Growth inhibition assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 0.20951 μM. | SANGER | ||
| HCC2998 | Growth inhibition assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 0.21157 μM. | SANGER | ||
| SW954 | Growth inhibition assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 0.21315 μM. | SANGER | ||
| EW-22 | Growth inhibition assay | Inhibition of human EW-22 cell growth in a cell viability assay, IC50 = 0.21795 μM. | SANGER | ||
| C8166 | Growth inhibition assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 0.22412 μM. | SANGER | ||
| LU-139 | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 0.23541 μM. | SANGER | ||
| ES3 | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 0.24258 μM. | SANGER | ||
| NCI-H1299 | Growth inhibition assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 0.25003 μM. | SANGER | ||
| NCI-H358 | Growth inhibition assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 0.25058 μM. | SANGER | ||
| OCI-AML2 | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 0.26563 μM. | SANGER | ||
| NCI-H1155 | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 0.26618 μM. | SANGER | ||
| AsPC-1 | Growth inhibition assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 0.26622 μM. | SANGER | ||
| LU-99A | Growth inhibition assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 0.27384 μM. | SANGER | ||
| OE33 | Growth inhibition assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 0.28167 μM. | SANGER | ||
| NCI-H1755 | Growth inhibition assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 0.28721 μM. | SANGER | ||
| NEC8 | Growth inhibition assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 0.28976 μM. | SANGER | ||
| NCI-H23 | Growth inhibition assay | Inhibition of human NCI-H23 cell growth in a cell viability assay, IC50 = 0.29321 μM. | SANGER | ||
| 5637 | Growth inhibition assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 0.29334 μM. | SANGER | ||
| NCI-H28 | Growth inhibition assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 0.29905 μM. | SANGER | ||
| HD-MY-Z | Growth inhibition assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50 = 0.30951 μM. | SANGER | ||
| LK-2 | Growth inhibition assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 0.31751 μM. | SANGER | ||
| NCI-H1048 | Growth inhibition assay | Inhibition of human NCI-H1048 cell growth in a cell viability assay, IC50 = 0.32842 μM. | SANGER | ||
| KYSE-450 | Growth inhibition assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 0.33447 μM. | SANGER | ||
| RH-1 | Growth inhibition assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 0.36182 μM. | SANGER | ||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 0.36582 μM. | SANGER | ||
| KM-H2 | Growth inhibition assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 0.3694 μM. | SANGER | ||
| Ca-Ski | Growth inhibition assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 0.37319 μM. | SANGER | ||
| VM-CUB-1 | Growth inhibition assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 0.37442 μM. | SANGER | ||
| TE-1 | Growth inhibition assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 0.38824 μM. | SANGER | ||
| HCC70 | Growth inhibition assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 0.38918 μM. | SANGER | ||
| IST-SL1 | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 0.3901 μM. | SANGER | ||
| HSC-2 | Growth inhibition assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 0.3987 μM. | SANGER | ||
| MHH-NB-11 | Growth inhibition assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 0.40951 μM. | SANGER | ||
| CAL-72 | Growth inhibition assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 0.41594 μM. | SANGER | ||
| LCLC-97TM1 | Growth inhibition assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 0.4222 μM. | SANGER | ||
| SF268 | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 0.42797 μM. | SANGER | ||
| ES6 | Growth inhibition assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 0.42837 μM. | SANGER | ||
| ES5 | Growth inhibition assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 0.43531 μM. | SANGER | ||
| NB7 | Growth inhibition assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50 = 0.4476 μM. | SANGER | ||
| NCI-H1666 | Growth inhibition assay | Inhibition of human NCI-H1666 cell growth in a cell viability assay, IC50 = 0.44879 μM. | SANGER | ||
| KARPAS-299 | Growth inhibition assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50 = 0.4935 μM. | SANGER | ||
| EW-24 | Growth inhibition assay | Inhibition of human EW-24 cell growth in a cell viability assay, IC50 = 0.49654 μM. | SANGER | ||
| COLO-668 | Growth inhibition assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 0.49856 μM. | SANGER | ||
| EW-18 | Growth inhibition assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.49994 μM. | SANGER | ||
| SK-MEL-1 | Growth inhibition assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 0.50044 μM. | SANGER | ||
| KG-1 | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 0.50853 μM. | SANGER | ||
| TE-12 | Growth inhibition assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 0.51068 μM. | SANGER | ||
| MSTO-211H | Growth inhibition assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50 = 0.51865 μM. | SANGER | ||
| ES8 | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 0.52199 μM. | SANGER | ||
| DSH1 | Growth inhibition assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50 = 0.53272 μM. | SANGER | ||
| 22RV1 | Growth inhibition assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 0.53688 μM. | SANGER | ||
| SW620 | Growth inhibition assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 0.54193 μM. | SANGER | ||
| Calu-6 | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 0.55272 μM. | SANGER | ||
| SBC-1 | Growth inhibition assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 0.56379 μM. | SANGER | ||
| EFO-27 | Growth inhibition assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 0.56741 μM. | SANGER | ||
| PC-14 | Growth inhibition assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 0.57286 μM. | SANGER | ||
| ME-180 | Growth inhibition assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 0.58774 μM. | SANGER | ||
| EW-11 | Growth inhibition assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 0.59737 μM. | SANGER | ||
| AM-38 | Growth inhibition assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 0.60387 μM. | SANGER | ||
| KINGS-1 | Growth inhibition assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 0.61454 μM. | SANGER | ||
| DMS-79 | Growth inhibition assay | Inhibition of human DMS-79 cell growth in a cell viability assay, IC50 = 0.62813 μM. | SANGER | ||
| G-401 | Growth inhibition assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 0.63901 μM. | SANGER | ||
| 786-0 | Growth inhibition assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 0.6433 μM. | SANGER | ||
| NCI-H2452 | Growth inhibition assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50 = 0.65063 μM. | SANGER | ||
| YAPC | Growth inhibition assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 0.66575 μM. | SANGER | ||
| CAKI-1 | Growth inhibition assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 0.67149 μM. | SANGER | ||
| NCI-H441 | Growth inhibition assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 0.67292 μM. | SANGER | ||
| OC-314 | Growth inhibition assay | Inhibition of human OC-314 cell growth in a cell viability assay, IC50 = 0.68605 μM. | SANGER | ||
| CFPAC-1 | Growth inhibition assay | Inhibition of human CFPAC-1 cell growth in a cell viability assay, IC50 = 0.68955 μM. | SANGER | ||
| CCRF-CEM | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 0.69581 μM. | SANGER | ||
| NY | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50 = 0.72299 μM. | SANGER | ||
| SK-N-DZ | Growth inhibition assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 0.74308 μM. | SANGER | ||
| BPH-1 | Growth inhibition assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 0.77241 μM. | SANGER | ||
| TE-11 | Growth inhibition assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 0.77321 μM. | SANGER | ||
| HCE-4 | Growth inhibition assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 0.77872 μM. | SANGER | ||
| HCT-116 | Growth inhibition assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 0.78769 μM. | SANGER | ||
| NCI-H82 | Growth inhibition assay | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50 = 0.78992 μM. | SANGER | ||
| GAMG | Growth inhibition assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 0.80497 μM. | SANGER | ||
| SCC-15 | Growth inhibition assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 0.80509 μM. | SANGER | ||
| NCI-H650 | Growth inhibition assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 0.80779 μM. | SANGER | ||
| OVCAR-3 | Growth inhibition assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 0.81002 μM. | SANGER | ||
| SNU-449 | Growth inhibition assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 0.82735 μM. | SANGER | ||
| NCI-H596 | Growth inhibition assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50 = 0.83344 μM. | SANGER | ||
| MKN45 | Growth inhibition assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 0.87229 μM. | SANGER | ||
| HCE-T | Growth inhibition assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 0.87584 μM. | SANGER | ||
| EW-16 | Growth inhibition assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 0.89475 μM. | SANGER | ||
| NCI-H1092 | Growth inhibition assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 0.92204 μM. | SANGER | ||
| SCH | Growth inhibition assay | Inhibition of human SCH cell growth in a cell viability assay, IC50 = 0.98447 μM. | SANGER | ||
| C2BBe1 | Growth inhibition assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 0.99616 μM. | SANGER | ||
| DU-145 | Growth inhibition assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50 = 1.01074 μM. | SANGER | ||
| ESS-1 | Growth inhibition assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 1.02691 μM. | SANGER | ||
| SK-HEP-1 | Growth inhibition assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 1.05335 μM. | SANGER | ||
| SK-MEL-3 | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 1.05593 μM. | SANGER | ||
| SK-MEL-24 | Growth inhibition assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 1.05605 μM. | SANGER | ||
| KU-19-19 | Growth inhibition assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 1.07752 μM. | SANGER | ||
| A204 | Growth inhibition assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 1.08408 μM. | SANGER | ||
| UACC-893 | Growth inhibition assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50 = 1.09512 μM. | SANGER | ||
| RERF-LC-MS | Growth inhibition assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 1.1107 μM. | SANGER | ||
| NCI-H727 | Growth inhibition assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 1.12799 μM. | SANGER | ||
| BALL-1 | Growth inhibition assay | Inhibition of human BALL-1 cell growth in a cell viability assay, IC50 = 1.18696 μM. | SANGER | ||
| PFSK-1 | Growth inhibition assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 1.20631 μM. | SANGER | ||
| KYSE-180 | Growth inhibition assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 1.21205 μM. | SANGER | ||
| KYSE-140 | Growth inhibition assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 1.24529 μM. | SANGER | ||
| L-428 | Growth inhibition assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50 = 1.2567 μM. | SANGER | ||
| HuO9 | Growth inhibition assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 1.32794 μM. | SANGER | ||
| MKN28 | Growth inhibition assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 1.33391 μM. | SANGER | ||
| BT-20 | Growth inhibition assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 1.35019 μM. | SANGER | ||
| NCI-H520 | Growth inhibition assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 1.38932 μM. | SANGER | ||
| ETK-1 | Growth inhibition assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 1.39588 μM. | SANGER | ||
| SK-N-AS | Growth inhibition assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 1.41783 μM. | SANGER | ||
| COLO-829 | Growth inhibition assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 1.42979 μM. | SANGER | ||
| NCI-H1563 | Growth inhibition assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 1.43368 μM. | SANGER | ||
| RCM-1 | Growth inhibition assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 1.46139 μM. | SANGER | ||
| NCI-SNU-5 | Growth inhibition assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 1.49968 μM. | SANGER | ||
| OE19 | Growth inhibition assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50 = 1.5446 μM. | SANGER | ||
| PSN1 | Growth inhibition assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50 = 1.58664 μM. | SANGER | ||
| A388 | Growth inhibition assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 1.605 μM. | SANGER | ||
| A673 | Growth inhibition assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 1.6053 μM. | SANGER | ||
| NCI-H1650 | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 1.62866 μM. | SANGER | ||
| NCI-H1437 | Growth inhibition assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 1.67736 μM. | SANGER | ||
| LB831-BLC | Growth inhibition assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 1.71151 μM. | SANGER | ||
| LAN-6 | Growth inhibition assay | Inhibition of human LAN-6 cell growth in a cell viability assay, IC50 = 1.74562 μM. | SANGER | ||
| WM-115 | Growth inhibition assay | Inhibition of human WM-115 cell growth in a cell viability assay, IC50 = 1.82733 μM. | SANGER | ||
| HMV-II | Growth inhibition assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50 = 1.87858 μM. | SANGER | ||
| KURAMOCHI | Growth inhibition assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50 = 1.88694 μM. | SANGER | ||
| A172 | Growth inhibition assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 1.89589 μM. | SANGER | ||
| SW1417 | Growth inhibition assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 1.91334 μM. | SANGER | ||
| SHP-77 | Growth inhibition assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50 = 1.91459 μM. | SANGER | ||
| M14 | Growth inhibition assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 1.94298 μM. | SANGER | ||
| RPMI-7951 | Growth inhibition assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 1.95297 μM. | SANGER | ||
| A2058 | Growth inhibition assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 1.98773 μM. | SANGER | ||
| GOTO | Growth inhibition assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 2.05352 μM. | SANGER | ||
| LC-2-ad | Growth inhibition assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 2.1627 μM. | SANGER | ||
| JVM-2 | Growth inhibition assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 2.18064 μM. | SANGER | ||
| A431 | Growth inhibition assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 2.1971 μM. | SANGER | ||
| LU-135 | Growth inhibition assay | Inhibition of human LU-135 cell growth in a cell viability assay, IC50 = 2.23007 μM. | SANGER | ||
| ZR-75-30 | Growth inhibition assay | Inhibition of human ZR-75-30 cell growth in a cell viability assay, IC50 = 2.23294 μM. | SANGER | ||
| MKN1 | Growth inhibition assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 2.24641 μM. | SANGER | ||
| Capan-2 | Growth inhibition assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 2.28226 μM. | SANGER | ||
| NCI-H1793 | Growth inhibition assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 2.3404 μM. | SANGER | ||
| KOSC-2 | Growth inhibition assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 2.34293 μM. | SANGER | ||
| HT55 | Growth inhibition assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 2.40807 μM. | SANGER | ||
| NCI-H1304 | Growth inhibition assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 2.40894 μM. | SANGER | ||
| NCI-H2052 | Growth inhibition assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 2.50968 μM. | SANGER | ||
| FTC-133 | Growth inhibition assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 2.51395 μM. | SANGER | ||
| HT-1197 | Growth inhibition assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 2.61232 μM. | SANGER | ||
| PC-3 | Growth inhibition assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 2.63741 μM. | SANGER | ||
| NCI-H1838 | Growth inhibition assay | Inhibition of human NCI-H1838 cell growth in a cell viability assay, IC50 = 2.71146 μM. | SANGER | ||
| IGR-1 | Growth inhibition assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 2.73874 μM. | SANGER | ||
| CAL-54 | Growth inhibition assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 2.79173 μM. | SANGER | ||
| C32 | Growth inhibition assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 2.9247 μM. | SANGER | ||
| MEL-HO | Growth inhibition assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 2.92893 μM. | SANGER | ||
| Saos-2 | Growth inhibition assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 2.9636 μM. | SANGER | ||
| C3A | Growth inhibition assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 2.98832 μM. | SANGER | ||
| EFO-21 | Growth inhibition assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 3.01666 μM. | SANGER | ||
| NTERA-S-cl-D1 | Growth inhibition assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 3.14874 μM. | SANGER | ||
| KP-4 | Growth inhibition assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 3.15403 μM. | SANGER | ||
| CAL-62 | Growth inhibition assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 3.17541 μM. | SANGER | ||
| HuH-7 | Growth inhibition assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 3.18889 μM. | SANGER | ||
| MDA-MB-157 | Growth inhibition assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 3.24593 μM. | SANGER | ||
| LN-405 | Growth inhibition assay | Inhibition of human LN-405 cell growth in a cell viability assay, IC50 = 3.36325 μM. | SANGER | ||
| KP-N-YS | Growth inhibition assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 3.3961 μM. | SANGER | ||
| Ca9-22 | Growth inhibition assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 3.40494 μM. | SANGER | ||
| HTC-C3 | Growth inhibition assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 3.44245 μM. | SANGER | ||
| TE-9 | Growth inhibition assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 3.47042 μM. | SANGER | ||
| NH-12 | Growth inhibition assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 3.5065 μM. | SANGER | ||
| NCI-H661 | Growth inhibition assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 3.56287 μM. | SANGER | ||
| KYSE-410 | Growth inhibition assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 3.63926 μM. | SANGER | ||
| U031 | Growth inhibition assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 3.6434 μM. | SANGER | ||
| DMS-273 | Growth inhibition assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 3.70551 μM. | SANGER | ||
| Mewo | Growth inhibition assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 3.73522 μM. | SANGER | ||
| HGC-27 | Growth inhibition assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 3.79874 μM. | SANGER | ||
| SK-MEL-30 | Growth inhibition assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 3.85121 μM. | SANGER | ||
| PANC-08-13 | Growth inhibition assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 3.88613 μM. | SANGER | ||
| CAMA-1 | Growth inhibition assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 3.93734 μM. | SANGER | ||
| SAS | Growth inhibition assay | Inhibition of human SAS cell growth in a cell viability assay, IC50 = 3.93781 μM. | SANGER | ||
| D-263MG | Growth inhibition assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 3.98399 μM. | SANGER | ||
| LU-65 | Growth inhibition assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 4.07799 μM. | SANGER | ||
| J82 | Growth inhibition assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 4.09942 μM. | SANGER | ||
| PANC-10-05 | Growth inhibition assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 4.31758 μM. | SANGER | ||
| NCI-H2291 | Growth inhibition assay | Inhibition of human NCI-H2291 cell growth in a cell viability assay, IC50 = 4.34085 μM. | SANGER | ||
| LS-513 | Growth inhibition assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 4.35308 μM. | SANGER | ||
| BxPC-3 | Growth inhibition assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 4.40682 μM. | SANGER | ||
| OVCAR-4 | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 4.41418 μM. | SANGER | ||
| KYSE-520 | Growth inhibition assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 4.45456 μM. | SANGER | ||
| CAL-51 | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 4.53264 μM. | SANGER | ||
| NOS-1 | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 4.55551 μM. | SANGER | ||
| TGBC24TKB | Growth inhibition assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 4.5853 μM. | SANGER | ||
| SW837 | Growth inhibition assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 4.59068 μM. | SANGER | ||
| SW872 | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 4.6002 μM. | SANGER | ||
| HuP-T3 | Growth inhibition assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 4.61839 μM. | SANGER | ||
| U-118-MG | Growth inhibition assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 4.67136 μM. | SANGER | ||
| MEL-JUSO | Growth inhibition assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 4.74418 μM. | SANGER | ||
| RKO | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 4.76289 μM. | SANGER | ||
| NCI-H510A | Growth inhibition assay | Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50 = 4.79154 μM. | SANGER | ||
| K-562 | Growth inhibition assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50 = 4.87506 μM. | SANGER | ||
| VA-ES-BJ | Growth inhibition assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 5.05884 μM. | SANGER | ||
| SK-MES-1 | Growth inhibition assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 5.06911 μM. | SANGER | ||
| VMRC-RCZ | Growth inhibition assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 5.07977 μM. | SANGER | ||
| EPLC-272H | Growth inhibition assay | Inhibition of human EPLC-272H cell growth in a cell viability assay, IC50 = 5.19957 μM. | SANGER | ||
| HCC1806 | Growth inhibition assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 5.25467 μM. | SANGER | ||
| NB13 | Growth inhibition assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 5.26073 μM. | SANGER | ||
| OS-RC-2 | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 5.32083 μM. | SANGER | ||
| NCI-H226 | Growth inhibition assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 5.35517 μM. | SANGER | ||
| NB10 | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 5.51218 μM. | SANGER | ||
| U-266 | Growth inhibition assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 5.52857 μM. | SANGER | ||
| SN12C | Growth inhibition assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 5.55432 μM. | SANGER | ||
| BHY | Growth inhibition assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 5.7258 μM. | SANGER | ||
| MDA-MB-453 | Growth inhibition assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 5.89794 μM. | SANGER | ||
| KNS-62 | Growth inhibition assay | Inhibition of human KNS-62 cell growth in a cell viability assay, IC50 = 5.91216 μM. | SANGER | ||
| SW1710 | Growth inhibition assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 5.96188 μM. | SANGER | ||
| NCI-N87 | Growth inhibition assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 6.03226 μM. | SANGER | ||
| MFM-223 | Growth inhibition assay | Inhibition of human MFM-223 cell growth in a cell viability assay, IC50 = 6.06013 μM. | SANGER | ||
| CAPAN-1 | Growth inhibition assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 6.09615 μM. | SANGER | ||
| HPAF-II | Growth inhibition assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 6.11846 μM. | SANGER | ||
| NUGC-3 | Growth inhibition assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 6.1225 μM. | SANGER | ||
| KLE | Growth inhibition assay | Inhibition of human KLE cell growth in a cell viability assay, IC50 = 6.15907 μM. | SANGER | ||
| KYSE-70 | Growth inhibition assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 6.16583 μM. | SANGER | ||
| HO-1-N-1 | Growth inhibition assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 6.17442 μM. | SANGER | ||
| RPMI-2650 | Growth inhibition assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 6.18782 μM. | SANGER | ||
| FADU | Growth inhibition assay | Inhibition of human FADU cell growth in a cell viability assay, IC50 = 6.28916 μM. | SANGER | ||
| 639-V | Growth inhibition assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 6.32379 μM. | SANGER | ||
| HCC1569 | Growth inhibition assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 6.37095 μM. | SANGER | ||
| SW1088 | Growth inhibition assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 6.44397 μM. | SANGER | ||
| HSC-4 | Growth inhibition assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50 = 6.47278 μM. | SANGER | ||
| NCI-H292 | Growth inhibition assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 6.47748 μM. | SANGER | ||
| NCI-H630 | Growth inhibition assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50 = 6.51861 μM. | SANGER | ||
| LXF-289 | Growth inhibition assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 6.56265 μM. | SANGER | ||
| SCC-25 | Growth inhibition assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 6.59415 μM. | SANGER | ||
| NCI-H1693 | Growth inhibition assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50 = 6.68028 μM. | SANGER | ||
| SKG-IIIa | Growth inhibition assay | Inhibition of human SKG-IIIa cell growth in a cell viability assay, IC50 = 6.78683 μM. | SANGER | ||
| LB2518-MEL | Growth inhibition assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 6.82267 μM. | SANGER | ||
| LS-1034 | Growth inhibition assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 6.86775 μM. | SANGER | ||
| HN | Growth inhibition assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 6.88448 μM. | SANGER | ||
| Detroit562 | Growth inhibition assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 6.92474 μM. | SANGER | ||
| SH-4 | Growth inhibition assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 6.94267 μM. | SANGER | ||
| JEG-3 | Growth inhibition assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 7.03192 μM. | SANGER | ||
| UM-UC-3 | Growth inhibition assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 7.03519 μM. | SANGER | ||
| DoTc2-4510 | Growth inhibition assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 7.05821 μM. | SANGER | ||
| HLE | Growth inhibition assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 7.0854 μM. | SANGER | ||
| BB65-RCC | Growth inhibition assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 7.08595 μM. | SANGER | ||
| RO82-W-1 | Growth inhibition assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 7.24089 μM. | SANGER | ||
| NCI-H1395 | Growth inhibition assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50 = 7.27989 μM. | SANGER | ||
| no-10 | Growth inhibition assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 7.30721 μM. | SANGER | ||
| SK-MEL-28 | Growth inhibition assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 7.39401 μM. | SANGER | ||
| SCC-9 | Growth inhibition assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 7.43344 μM. | SANGER | ||
| DOK | Growth inhibition assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 7.58205 μM. | SANGER | ||
| SK-LU-1 | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 7.59839 μM. | SANGER | ||
| SCC-4 | Growth inhibition assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 7.60907 μM. | SANGER | ||
| TGBC1TKB | Growth inhibition assay | Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50 = 7.61741 μM. | SANGER | ||
| CAL-33 | Growth inhibition assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 7.67712 μM. | SANGER | ||
| NCI-H2228 | Growth inhibition assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 7.68712 μM. | SANGER | ||
| D-283MED | Growth inhibition assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 7.7046 μM. | SANGER | ||
| ChaGo-K-1 | Growth inhibition assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 7.73826 μM. | SANGER | ||
| NCI-H1651 | Growth inhibition assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 7.80243 μM. | SANGER | ||
| CHP-212 | Growth inhibition assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 7.84741 μM. | SANGER | ||
| NCI-H2170 | Growth inhibition assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 7.85967 μM. | SANGER | ||
| PANC-03-27 | Growth inhibition assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 7.92715 μM. | SANGER | ||
| SW13 | Growth inhibition assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 8.0437 μM. | SANGER | ||
| HEC-1 | Growth inhibition assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 8.07574 μM. | SANGER | ||
| HCC1937 | Growth inhibition assay | Inhibition of human HCC1937 cell growth in a cell viability assay, IC50 = 8.17918 μM. | SANGER | ||
| HT-144 | Growth inhibition assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 8.20687 μM. | SANGER | ||
| SK-PN-DW | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 8.35661 μM. | SANGER | ||
| OAW-42 | Growth inhibition assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 8.41744 μM. | SANGER | ||
| MDA-MB-415 | Growth inhibition assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50 = 8.42465 μM. | SANGER | ||
| CAL-12T | Growth inhibition assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 8.43014 μM. | SANGER | ||
| RD | Growth inhibition assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 8.43719 μM. | SANGER | ||
| SiHa | Growth inhibition assay | Inhibition of human SiHa cell growth in a cell viability assay, IC50 = 8.50233 μM. | SANGER | ||
| TCCSUP | Growth inhibition assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 8.56961 μM. | SANGER | ||
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 8.69038 μM. | SANGER | ||
| TE-8 | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 8.75699 μM. | SANGER | ||
| GAK | Growth inhibition assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 8.80609 μM. | SANGER | ||
| MZ1-PC | Growth inhibition assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 8.83346 μM. | SANGER | ||
| HuP-T4 | Growth inhibition assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 8.84849 μM. | SANGER | ||
| BFTC-905 | Growth inhibition assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 9.01606 μM. | SANGER | ||
| KALS-1 | Growth inhibition assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 9.08399 μM. | SANGER | ||
| MIA-PaCa-2 | Growth inhibition assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 9.12528 μM. | SANGER | ||
| EKVX | Growth inhibition assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 9.12941 μM. | SANGER | ||
| NCI-H2030 | Growth inhibition assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 9.18352 μM. | SANGER | ||
| BFTC-909 | Growth inhibition assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 9.20864 μM. | SANGER | ||
| SW684 | Growth inhibition assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50 = 9.28187 μM. | SANGER | ||
| 647-V | Growth inhibition assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 9.30722 μM. | SANGER | ||
| A498 | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 9.37367 μM. | SANGER | ||
| AN3-CA | Growth inhibition assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 9.489 μM. | SANGER | ||
| MC-IXC | Growth inhibition assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 9.51289 μM. | SANGER | ||
| LNCaP-Clone-FGC | Growth inhibition assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 9.57798 μM. | SANGER | ||
| UMC-11 | Growth inhibition assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50 = 9.58354 μM. | SANGER | ||
| GP5d | Growth inhibition assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 9.61403 μM. | SANGER | ||
| KNS-81-FD | Growth inhibition assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 9.63243 μM. | SANGER | ||
| CAL-27 | Growth inhibition assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 9.6443 μM. | SANGER | ||
| DMS-114 | Growth inhibition assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50 = 9.64704 μM. | SANGER | ||
| BEN | Growth inhibition assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 9.70411 μM. | SANGER | ||
| NCI-H2347 | Growth inhibition assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 9.71696 μM. | SANGER | ||
| A375 | Growth inhibition assay | Inhibition of human A375 cell growth in a cell viability assay, IC50 = 9.81646 μM. | SANGER | ||
| MZ2-MEL | Growth inhibition assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 9.82677 μM. | SANGER | ||
| PA-1 | Growth inhibition assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 9.89778 μM. | SANGER | ||
| OVCAR-8 | Growth inhibition assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 9.99071 μM. | SANGER | ||
| NCI-H2087 | Growth inhibition assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 10.1667 μM. | SANGER | ||
| BB49-HNC | Growth inhibition assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 10.1864 μM. | SANGER | ||
| HSC-3 | Growth inhibition assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 10.2833 μM. | SANGER | ||
| LS-123 | Growth inhibition assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 10.2892 μM. | SANGER | ||
| EFM-19 | Growth inhibition assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 10.5923 μM. | SANGER | ||
| EC-GI-10 | Growth inhibition assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50 = 10.6256 μM. | SANGER | ||
| C-33-A | Growth inhibition assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 10.6854 μM. | SANGER | ||
| RMG-I | Growth inhibition assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 10.693 μM. | SANGER | ||
| GT3TKB | Growth inhibition assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 10.7147 μM. | SANGER | ||
| KS-1 | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 10.7687 μM. | SANGER | ||
| S-117 | Growth inhibition assay | Inhibition of human S-117 cell growth in a cell viability assay, IC50 = 10.8166 μM. | SANGER | ||
| CAL-120 | Growth inhibition assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 10.8389 μM. | SANGER | ||
| NCI-H1355 | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 10.878 μM. | SANGER | ||
| CAL-85-1 | Growth inhibition assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 10.9405 μM. | SANGER | ||
| HOS | Growth inhibition assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 11.0071 μM. | SANGER | ||
| SW982 | Growth inhibition assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 11.017 μM. | SANGER | ||
| TE-6 | Growth inhibition assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 11.0327 μM. | SANGER | ||
| NCI-H446 | Growth inhibition assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 11.1658 μM. | SANGER | ||
| MZ7-mel | Growth inhibition assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 11.1829 μM. | SANGER | ||
| no-11 | Growth inhibition assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50 = 11.1956 μM. | SANGER | ||
| SW900 | Growth inhibition assay | Inhibition of human SW900 cell growth in a cell viability assay, IC50 = 11.2399 μM. | SANGER | ||
| MPP-89 | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 11.2566 μM. | SANGER | ||
| NMC-G1 | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 11.3482 μM. | SANGER | ||
| SW1463 | Growth inhibition assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 11.3769 μM. | SANGER | ||
| H4 | Growth inhibition assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 11.4757 μM. | SANGER | ||
| SW1573 | Growth inhibition assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 11.5198 μM. | SANGER | ||
| A549 | Growth inhibition assay | Inhibition of human A549 cell growth in a cell viability assay, IC50 = 11.5899 μM. | SANGER | ||
| TI-73 | Growth inhibition assay | Inhibition of human TI-73 cell growth in a cell viability assay, IC50 = 11.6051 μM. | SANGER | ||
| D-336MG | Growth inhibition assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 11.8898 μM. | SANGER | ||
| COLO-678 | Growth inhibition assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 11.98 μM. | SANGER | ||
| HCC1954 | Growth inhibition assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 11.9911 μM. | SANGER | ||
| TE-5 | Growth inhibition assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 11.9923 μM. | SANGER | ||
| MKN7 | Growth inhibition assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 12.0639 μM. | SANGER | ||
| SK-UT-1 | Growth inhibition assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 12.1697 μM. | SANGER | ||
| U251 | Growth inhibition assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 12.1928 μM. | SANGER | ||
| 8505C | Growth inhibition assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 12.2121 μM. | SANGER | ||
| CP50-MEL-B | Growth inhibition assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 12.2925 μM. | SANGER | ||
| MDA-MB-361 | Growth inhibition assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 12.2938 μM. | SANGER | ||
| SNU-387 | Growth inhibition assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 12.3426 μM. | SANGER | ||
| GCIY | Growth inhibition assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 12.3853 μM. | SANGER | ||
| SF295 | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 12.4198 μM. | SANGER | ||
| BT-474 | Growth inhibition assay | Inhibition of human BT-474 cell growth in a cell viability assay, IC50 = 12.5418 μM. | SANGER | ||
| TE-10 | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 12.6585 μM. | SANGER | ||
| Daoy | Growth inhibition assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 12.6833 μM. | SANGER | ||
| Becker | Growth inhibition assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 12.7925 μM. | SANGER | ||
| T98G | Growth inhibition assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 12.8459 μM. | SANGER | ||
| SW1116 | Growth inhibition assay | Inhibition of human SW1116 cell growth in a cell viability assay, IC50 = 12.8841 μM. | SANGER | ||
| SW48 | Growth inhibition assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 12.9525 μM. | SANGER | ||
| HT-1080 | Growth inhibition assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 12.9922 μM. | SANGER | ||
| SW962 | Growth inhibition assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 12.9963 μM. | SANGER | ||
| NCI-H747 | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 13.0773 μM. | SANGER | ||
| NCI-H1623 | Growth inhibition assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 13.1175 μM. | SANGER | ||
| SK-N-FI | Growth inhibition assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 13.1842 μM. | SANGER | ||
| CaR-1 | Growth inhibition assay | Inhibition of human CaR-1 cell growth in a cell viability assay, IC50 = 13.2168 μM. | SANGER | ||
| NCI-H1573 | Growth inhibition assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50 = 13.2177 μM. | SANGER | ||
| NCI-H2126 | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 13.7158 μM. | SANGER | ||
| IA-LM | Growth inhibition assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 13.723 μM. | SANGER | ||
| LoVo | Growth inhibition assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 13.7444 μM. | SANGER | ||
| MFE-280 | Growth inhibition assay | Inhibition of human MFE-280 cell growth in a cell viability assay, IC50 = 13.761 μM. | SANGER | ||
| LB2241-RCC | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 13.7984 μM. | SANGER | ||
| HCC1419 | Growth inhibition assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50 = 13.8122 μM. | SANGER | ||
| OAW-28 | Growth inhibition assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 13.8525 μM. | SANGER | ||
| RXF393 | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 13.8527 μM. | SANGER | ||
| SW756 | Growth inhibition assay | Inhibition of human SW756 cell growth in a cell viability assay, IC50 = 13.8609 μM. | SANGER | ||
| T-24 | Growth inhibition assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 13.9548 μM. | SANGER | ||
| NB5 | Growth inhibition assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 14.2275 μM. | SANGER | ||
| COLO-824 | Growth inhibition assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 14.2897 μM. | SANGER | ||
| NCI-H810 | Growth inhibition assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 14.3159 μM. | SANGER | ||
| OVCAR-5 | Growth inhibition assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 14.6687 μM. | SANGER | ||
| NB69 | Growth inhibition assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 14.7321 μM. | SANGER | ||
| NCI-H1648 | Growth inhibition assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 14.8041 μM. | SANGER | ||
| A101D | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 14.9363 μM. | SANGER | ||
| HT-1376 | Growth inhibition assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 14.9943 μM. | SANGER | ||
| M059J | Growth inhibition assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 15.1239 μM. | SANGER | ||
| LB1047-RCC | Growth inhibition assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 15.2239 μM. | SANGER | ||
| Calu-3 | Growth inhibition assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 15.2992 μM. | SANGER | ||
| GB-1 | Growth inhibition assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 15.3998 μM. | SANGER | ||
| D-247MG | Growth inhibition assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50 = 15.5928 μM. | SANGER | ||
| SJSA-1 | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 15.6585 μM. | SANGER | ||
| SW1783 | Growth inhibition assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 15.7647 μM. | SANGER | ||
| CW-2 | Growth inhibition assay | Inhibition of human CW-2 cell growth in a cell viability assay, IC50 = 15.7772 μM. | SANGER | ||
| RH-18 | Growth inhibition assay | Inhibition of human RH-18 cell growth in a cell viability assay, IC50 = 15.8004 μM. | SANGER | ||
| A427 | Growth inhibition assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 16.1842 μM. | SANGER | ||
| MCF7 | Growth inhibition assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 16.1989 μM. | SANGER | ||
| HuCCT1 | Growth inhibition assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 16.3275 μM. | SANGER | ||
| SNU-423 | Growth inhibition assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 16.347 μM. | SANGER | ||
| ACN | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 16.3789 μM. | SANGER | ||
| SW626 | Growth inhibition assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 16.4693 μM. | SANGER | ||
| CAS-1 | Growth inhibition assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 16.5667 μM. | SANGER | ||
| GCT | Growth inhibition assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 16.5942 μM. | SANGER | ||
| HOP-92 | Growth inhibition assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 16.6539 μM. | SANGER | ||
| NB17 | Growth inhibition assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50 = 16.8323 μM. | SANGER | ||
| COR-L105 | Growth inhibition assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 16.8635 μM. | SANGER | ||
| COLO-792 | Growth inhibition assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 16.9659 μM. | SANGER | ||
| SK-MEL-2 | Growth inhibition assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 17.0576 μM. | SANGER | ||
| DK-MG | Growth inhibition assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 17.3929 μM. | SANGER | ||
| CAL-39 | Growth inhibition assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 17.4072 μM. | SANGER | ||
| MDA-MB-175-VII | Growth inhibition assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 17.4297 μM. | SANGER | ||
| T84 | Growth inhibition assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 17.5368 μM. | SANGER | ||
| HCC38 | Growth inhibition assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 17.5671 μM. | SANGER | ||
| LB771-HNC | Growth inhibition assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 17.7199 μM. | SANGER | ||
| UACC-62 | Growth inhibition assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50 = 17.9158 μM. | SANGER | ||
| SF126 | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 17.9625 μM. | SANGER | ||
| SW1990 | Growth inhibition assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 18.0631 μM. | SANGER | ||
| TGBC11TKB | Growth inhibition assay | Inhibition of human TGBC11TKB cell growth in a cell viability assay, IC50 = 18.2546 μM. | SANGER | ||
| U-87-MG | Growth inhibition assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 18.5606 μM. | SANGER | ||
| COLO-679 | Growth inhibition assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 18.5837 μM. | SANGER | ||
| SW948 | Growth inhibition assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 18.6269 μM. | SANGER | ||
| KP-N-YN | Growth inhibition assay | Inhibition of human KP-N-YN cell growth in a cell viability assay, IC50 = 18.8494 μM. | SANGER | ||
| SF539 | Growth inhibition assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 19.0902 μM. | SANGER | ||
| UACC-257 | Growth inhibition assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 19.2295 μM. | SANGER | ||
| GI-1 | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 19.4924 μM. | SANGER | ||
| MMAC-SF | Growth inhibition assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 19.5532 μM. | SANGER | ||
| COLO-680N | Growth inhibition assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 19.5982 μM. | SANGER | ||
| NB12 | Growth inhibition assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 19.6531 μM. | SANGER | ||
| EGI-1 | Growth inhibition assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 19.9713 μM. | SANGER | ||
| RCC10RGB | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 20.2102 μM. | SANGER | ||
| DJM-1 | Growth inhibition assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 20.25 μM. | SANGER | ||
| NCI-H1703 | Growth inhibition assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 20.3088 μM. | SANGER | ||
| IST-MES1 | Growth inhibition assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 20.6658 μM. | SANGER | ||
| H-EMC-SS | Growth inhibition assay | Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50 = 20.775 μM. | SANGER | ||
| ABC-1 | Growth inhibition assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 21.1496 μM. | SANGER | ||
| YH-13 | Growth inhibition assay | Inhibition of human YH-13 cell growth in a cell viability assay, IC50 = 21.4065 μM. | SANGER | ||
| G-402 | Growth inhibition assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 21.5781 μM. | SANGER | ||
| NCI-H2342 | Growth inhibition assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 21.6184 μM. | SANGER | ||
| 8-MG-BA | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 21.8056 μM. | SANGER | ||
| GMS-10 | Growth inhibition assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 21.8427 μM. | SANGER | ||
| D-566MG | Growth inhibition assay | Inhibition of human D-566MG cell growth in a cell viability assay, IC50 = 21.869 μM. | SANGER | ||
| OCUB-M | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 22.2462 μM. | SANGER | ||
| A704 | Growth inhibition assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 22.8145 μM. | SANGER | ||
| MDA-MB-231 | Growth inhibition assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 22.898 μM. | SANGER | ||
| D-502MG | Growth inhibition assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 22.9462 μM. | SANGER | ||
| KNS-42 | Growth inhibition assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 22.9791 μM. | SANGER | ||
| RVH-421 | Growth inhibition assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 23.0443 μM. | SANGER | ||
| NCI-H1993 | Growth inhibition assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 23.1883 μM. | SANGER | ||
| HCC1395 | Growth inhibition assay | Inhibition of human HCC1395 cell growth in a cell viability assay, IC50 = 23.2308 μM. | SANGER | ||
| YKG-1 | Growth inhibition assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 23.243 μM. | SANGER | ||
| D-423MG | Growth inhibition assay | Inhibition of human D-423MG cell growth in a cell viability assay, IC50 = 23.8285 μM. | SANGER | ||
| OMC-1 | Growth inhibition assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 24.6212 μM. | SANGER | ||
| Hs-578-T | Growth inhibition assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 24.7097 μM. | SANGER | ||
| SNB75 | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 24.7751 μM. | SANGER | ||
| T47D | Growth inhibition assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 24.8783 μM. | SANGER | ||
| NCI-H2029 | Growth inhibition assay | Inhibition of human NCI-H2029 cell growth in a cell viability assay, IC50 = 25.7967 μM. | SANGER | ||
| NB6 | Growth inhibition assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 25.8767 μM. | SANGER | ||
| BHT-101 | Growth inhibition assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 26.6443 μM. | SANGER | ||
| TK10 | Growth inhibition assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 26.8495 μM. | SANGER | ||
| NCI-H2405 | Growth inhibition assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 29.0895 μM. | SANGER | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Methotrexate,一種葉酸類似物，是細菌、癌細胞和正常細胞中dihydrofolate reductase(DHFR)的非選擇性抑制劑，與DHFR、NADPH形成無活性的三元復合物。Methotrexate (MTX)可誘導凋亡。 | ||
|---|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | Methotrexate (0.1-10 mM)誘導體外活化的來自人類外周血的T細胞的細胞凋亡。在混合淋巴細胞反應中，Methotrexate使活化的T細胞的克隆缺失。Methotrexate能夠通過CD95不依賴的途徑選擇性刪除活化的外周血中T細胞。[1] Methotrexate通過還原性葉酸載體被細胞利用，隨后在細胞內(nèi)被轉(zhuǎn)化為聚谷氨酸鹽。Methotrexate導致體外中性粒細胞刺激的白三烯B4的產(chǎn)生減少。Methotrexate聚谷氨酸鹽抑制5-氨基咪唑-4-氨甲酰核糖核苷 (AICAR)甲?；D(zhuǎn)移酶，比對其他參與嘌呤生物合成的酶更加有效。Methotrexate也通過抑制體外TNF誘導的核因子κB活化而抑制TNF活性，與該因子，IκBα的一個抑制劑的降解和活化的減少部分相關(guān)，也可能與腺苷的釋放有關(guān)。Methotrexate通過來自健康人體和RA患者的T細胞受體激活的T淋巴細胞抑制TNF 和IFN-γ的產(chǎn)生。Methotrexate的治療與TNF-α陽性的CD4+ T 細胞顯著減少，而T細胞表達的抗炎因子IL-10的數(shù)量增加有關(guān)。[2] |
|||
|---|---|---|---|---|
| 實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
| Western blot | ppJAK1 / ppJAK2 / JAK1 / JAK2 pSTAT1 / pSTAT3 / pSTAT5 / STAT1 / STAT3 / STAT5 AKT / p-AKT / mTOR / p-mTOR / Beclin 1 / HMGB1 |
|
26131691 | |
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | 在小鼠體內(nèi)，Methotrexate增加脾細胞中AICAR含量，升高了角叉菜膠發(fā)炎氣泡的滲出液中腺苷濃度，并且顯著抑制了發(fā)炎氣泡中白血球的積累。在小鼠體內(nèi)，Methotrexate介導的白血球累積的減少被注射腺苷脫氨酶（ADA）到氣泡而部分逆轉(zhuǎn)，被特定的腺苷A2受體拮抗劑，3,7-dimethyl-1-propargylxanthine (DMPX)完全逆轉(zhuǎn)，但不會被腺苷A1受體拮抗劑，8-cyclopentyl-dipropylxanthine所影響。[3] |
|
|---|---|---|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06324604 | Not yet recruiting | Healthy Volunteers|Celiac Disease|Type 1 Diabetes |
Mozart Therapeutics Australia Pty Ltd |
June 2024 | Phase 1 |
| NCT06401213 | Recruiting | Healthy |
Mediar Therapeutics|ICON plc |
April 15 2024 | Phase 1 |
| NCT06281184 | Not yet recruiting | Hand Osteoarthritis|Erosive Osteoarthritis |
Diakonhjemmet Hospital |
March 15 2024 | -- |
| NCT06300333 | Not yet recruiting | Ectopic Pregnancy |
Assiut University |
March 2024 | -- |
| NCT06277635 | Recruiting | Rheumatoid Arthritis|Psoriatic Arthritis|Psoriasis |
Phramongkutklao College of Medicine and Hospital |
February 1 2024 | Not Applicable |
化學信息&溶解度
| 分子量 | 454.44 | 分子式 | C20H22N8O5 |
| CAS號 | 59-05-2 | SDF | Download Methotrexate SDF |
| Smiles | CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O | ||
| 儲存條件(自收到貨起) | 3年 -20°C(避光) 粉狀 1年 -80°C(避光) 溶于溶劑 |
||
|
體外溶解度 |
DMSO : 91 mg/mL ( (200.24 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | ||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
Tags: buy Methotrexate | Methotrexate supplier | purchase Methotrexate | Methotrexate cost | Methotrexate manufacturer | order Methotrexate | Methotrexate distributor
